Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | See Remarks | February 11, 2021 | February 16, 2021 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | See Remarks | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 · Expires 2031-02-10 | Direct | 67,700 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 67,700 · Balance 67,700 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021.
TScan Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 304,716 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 300,000 · Balance 304,716 F1: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:45 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantVoting Common Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-412518 · ownership.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,716 F1 · kind: 25% of the restricted stock units ("RSUs") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:19 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001193125-26-019674 · ownership.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Voting Common Stock · 350,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Feb 11, 2025 22:54 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000950170-25-018131 · ownership.xml · derivative · entry 2 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Voting Common Stock · 250,000 shares Expires 2035-01-03 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionStock Option (Right to Buy) · Derivative | 64,166 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · derivative · entry 9 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,834 Underlying: Voting Common Stock · 64,166 shares Expires 2033-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,125 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · derivative · entry 8 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,875 Underlying: Voting Common Stock · 13,125 shares Expires 2033-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · derivative · entry 7 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Voting Common Stock · 25,000 shares Expires 2032-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionStock Option (Right to Buy) · Derivative | 54,895 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · derivative · entry 6 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,105 Underlying: Voting Common Stock · 54,895 shares Expires 2032-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | SaleVoting Common Stock | 164,686 | $5.78 | $952,115.64 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · nonDerivative · entry 5 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,716 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionVoting Common Stock | 64,166 | $2.49 | $159,773.34 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · nonDerivative · entry 4 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionVoting Common Stock | 13,125 | $1.81 | $23,756.25 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · nonDerivative · entry 3 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionVoting Common Stock | 25,000 | $3.27 | $81,750.00 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · nonDerivative · entry 2 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 22:46 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | Exercise / conversionVoting Common Stock | 54,895 | $4.85 | $266,240.75 |
DisclosureSEC source: 0000950170-24-101161 · ownership.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 31, 2022. Read SEC document |
| January 12, 2024 Filed Feb 11, 2025 22:54 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000950170-25-018131 · ownership.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Voting Common Stock · 52,500 shares Expires 2034-01-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:01 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 430,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0000899243-23-015632 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,000 Underlying: Voting Common Stock · 430,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: 220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 22:15 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-23-004064 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Voting Common Stock · 35,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 20:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-22-026847 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Voting Common Stock · 50,000 shares Expires 2032-07-24 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:25 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0000899243-22-002646 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Voting Common Stock · 85,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 21:22 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | PurchaseVoting Common Stock | 4,716 | $7.48 | $35,255.40 |
DisclosureSEC source: 0000899243-21-037802 · doc4.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,716 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $7.43 to $7.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:21 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0000899243-21-035470 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Voting Common Stock · 150,000 shares Expires 2031-09-06 F1 · derivative.exercise_date: The shares subject to this option will vest with respect to 25% of the shares after 12 months of continuous service to the Issuer following September 7, 2021, and the balance will vest in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:47 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 67,700 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0000899243-21-006713 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,700 Underlying: Common Stock · 67,700 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:11 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-20-004308 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 21:11 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 7,902 | $16.00 | $126,432.00 |
DisclosureSEC source: 0001562180-19-006265 · primarydocument.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,009 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 24, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 820 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · derivative · entry 8 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,856 Underlying: Common Stock · 820 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise. F7 · derivative.exercise_date: This option vests and becomes exercisable in 16 equal quarterly installments beginning on January 1, 2018. Read SEC document |
| December 24, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 7,902 | $16.00 | $126,432.00 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 5 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,010 F2 · kind: This trade is pursuant to an active 10b5-1 plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F5 · balance_after: Balance has been updated to reflect the shares acquired and sold on the form 4 filed 12/26/2019. Read SEC document |
| December 24, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 820 | $7.71 | $6,322.20 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 4 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 15:13 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 4,181 | $16.03 | $67,021.43 |
DisclosureSEC source: 0001562180-19-006261 · primarydocument.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,911 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 23, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · derivative · entry 7 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,676 Underlying: Common Stock · 9 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise. F7 · derivative.exercise_date: This option vests and becomes exercisable in 16 equal quarterly installments beginning on January 1, 2018. Read SEC document |
| December 23, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,172 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · derivative · entry 6 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,342 Underlying: Common Stock · 4,172 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise. F6 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments beginning on the date of effectiveness of the Issuer's Registration Statement on Form S-1. Read SEC document |
| December 23, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 4,181 | $16.03 | $67,041.08 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 3 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,092 F2 · kind: This trade is pursuant to an active 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 23, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 4,172 | $9.49 | $39,592.28 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 2 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise. Read SEC document |
| December 23, 2019 Filed Dec 30, 2019 22:39 UTC Amendment | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Exercise / conversionCommon Stock | 9 | $7.71 | $69.39 |
DisclosureSEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:23 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002874 · doc4.xml · derivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries C Preferred Stock · Derivative | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018332 · doc4.xml · derivative · entry 2 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 4,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018332 · doc4.xml · nonDerivative · entry 1 ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.